三力制药：2025年年度业绩预减公告

Core Viewpoint - Sanli Pharmaceutical announced an expected net profit attributable to shareholders of the parent company for 2025 to be between 36 million and 52 million yuan, representing a significant decrease compared to the previous year's figure of 274.03 million yuan, indicating a decline of 22.02 million to 23.80 million yuan, or a year-on-year decrease of 81.02% to 86.86% [1] Financial Performance - The projected net profit for 2025 is estimated to be between 36 million yuan and 52 million yuan [1] - This represents a decrease of 22.02 million to 23.80 million yuan compared to the previous year's net profit of 274.03 million yuan [1] - The year-on-year decline percentage is estimated to be between 81.02% and 86.86% [1]